Caturegli P, Mariotti S, Kuppers R C, Burek C L, Pinchera A, Rose N R
Department of Immunology and Infectious Diseases, Johns Hopkins University School of Hygiene and Public Health, Baltimore, MD 21205.
Autoimmunity. 1994;18(1):41-9. doi: 10.3109/08916939409014678.
Thyroglobulin antibodies (TgAbs) are typically found in autoimmune thyroid diseases and, more rarely, in nonautoimmune thyroid diseases and healthy subjects. To determine whether TgAbs associated with different conditions recognize different epitopes on the thyroglobulin molecule, we studied 28 patients with Hashimoto's thyroiditis, 30 with Graves' disease, 21 with thyroid carcinoma, 18 with nontoxic goiter, and 25 healthy subjects. All patients were selected for the presence of TgAbs; 4/25 healthy subjects also had TgAbs. The sera were assayed for the their ability to inhibit the binding of monoclonal antibodies to thyroglobulin in an ELISA assay. We found that: 1) TgAbs in Hashimoto's patients preferentially recognized three clusters of epitopes (II, III and typically VI), with no difference between the goitrous and the atrophic variants; 2) TgAbs in Graves' patients were directed toward cluster II, with no difference between the presence or the absence of ophthalmopathy; 3) TgAbs in thyroid carcinoma patients recognized the same clusters as Hashimoto's patients; 4) TgAbs in nontoxic goiter patients and in the four healthy subjects showed no restriction in epitope recognition. We suggest that in individuals with no overt clinical or biochemical thyroid abnormalities but with TgAbs, the finding that these TgAbs recognize particular immunodominant clusters may be utilized to predict full-blown thyroid disorders. Longitudinal studies are needed to evaluate the possible clinical application of this methodology.
甲状腺球蛋白抗体(TgAbs)通常见于自身免疫性甲状腺疾病,在非自身免疫性甲状腺疾病及健康受试者中则较为少见。为确定与不同病症相关的TgAbs是否识别甲状腺球蛋白分子上的不同表位,我们研究了28例桥本甲状腺炎患者、30例格雷夫斯病患者、21例甲状腺癌患者、18例非毒性甲状腺肿患者以及25名健康受试者。所有患者均因存在TgAbs而入选;25名健康受试者中有4人也有TgAbs。采用酶联免疫吸附测定法检测血清抑制单克隆抗体与甲状腺球蛋白结合的能力。我们发现:1)桥本甲状腺炎患者的TgAbs优先识别三个表位簇(II、III及典型的VI),甲状腺肿型与萎缩型之间无差异;2)格雷夫斯病患者的TgAbs针对表位簇II,有无眼病之间无差异;3)甲状腺癌患者的TgAbs识别的表位簇与桥本甲状腺炎患者相同;4)非毒性甲状腺肿患者及4名健康受试者的TgAbs在表位识别上无限制。我们认为,对于无明显临床或生化甲状腺异常但有TgAbs的个体,这些TgAbs识别特定免疫显性簇这一发现可用于预测全面的甲状腺疾病。需要进行纵向研究以评估该方法的可能临床应用。